How is Teladoc Health Placed in the Growing Telemedicine Market?
Werte in diesem Artikel
Teladoc Health TDOC, a leading global provider of virtual healthcare, is well-positioned to capitalize on the evolving dynamics of the telemedicine market. Telemedicine is revolutionizing healthcare access, supported by regulatory measures such as the 1135 waiver and the Coronavirus Preparedness Act, which expanded Medicare coverage for telehealth visits across offices, hospitals, and patients’ homes. This growing demand for remote medical services continues to accelerate the adoption of telehealth solutions, directly benefiting industry leader Teladoc.In July 2023, Teladoc strengthened its technological edge by extending its partnership with Microsoft to integrate advanced AI into its Solo platform. This collaboration aims to automate clinical documentation during virtual consultations while enhancing care quality. With an estimated U.S. total addressable market of $261 billion, Teladoc’s comprehensive offerings position it to capture substantial market share.According to a Towards Healthcare report, the U.S. telehealth market, valued at $42.61 billion in 2024, is projected to rise to $52.76 billion in 2025 and reach $358.96 billion by 2034. Teladoc’s broad suite of integrated services—spanning non-urgent consultations to complex chronic-care management—enables it to serve diverse patient needs and fully leverage this expansion.Although the company continues to incur losses due to heavy investments in client acquisition, provider network development, and technology innovation, these expenditures strengthen its competitive position. As the most comprehensive player in virtual care, Teladoc aims to become the primary “front door” to the healthcare system for millions of members worldwide.What About TDOC’s Peers?HCA Healthcare HCA and CVS Health Corporation CVS are well-positioned to capitalize on the rapid growth of the telemedicine market. HCA Healthcare is integrating virtual care across its extensive network of hospitals and physicians, improving accessibility and continuity of treatment for patients. Meanwhile, CVS Health leverages its MinuteClinic and Virtual Care services to merge telehealth with its broad retail and pharmacy footprint, delivering affordable, convenient and connected care. Both HCA Healthcare and CVS Health continue to invest heavily in digital health infrastructure, remote monitoring and strategic partnerships, enabling them to capitalize on the opportunities in the evolving healthcare landscape.TDOC’s Price PerformanceShares of Teladoc have lost 17.2% year to date against the industry’s increase of 3.1%.Image Source: Zacks Investment ResearchTDOC’s Expensive ValuationTDOC is trading at a forward 12-month price-to-sales multiple of 0.53, higher than the industry average of 0.45.Image Source: Zacks Investment ResearchEstimates Movement for TDOCThe Zacks Consensus Estimate for TDOC’s fourth-quarter 2025 loss has narrowed by 1 cent, while that for the first-quarter 2026 loss has improved by 2 cents over the past 30 days. While the consensus estimate for full-year 2025 witnessed no movement, the one for 2026 loss has narrowed 3 cents in the same time frame. Image Source: Zacks Investment ResearchThe consensus estimate for TDOC’s 2025 revenues indicates a year-over-year decline, but the same for 2026 suggests a year-over-year increase. The consensus estimates for 2025 and 2026 EPS indicate year-over-year increases.TDOC stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They includeStock #1: A Disruptive Force with Notable Growth and ResilienceStock #2: Bullish Signs Signaling to Buy the DipStock #3: One of the Most Compelling Investments in the MarketStock #4: Leader In a Red-Hot Industry Poised for GrowthStock #5: Modern Omni-Channel Platform Coiled to SpringMost of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.Download Atomic Opportunity: Nuclear Energy's Comeback free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CVS Health Corporation (CVS): Free Stock Analysis Report HCA Healthcare, Inc. (HCA): Free Stock Analysis Report Teladoc Health, Inc. (TDOC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: Teladoc und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!
Ausgewählte Hebelprodukte auf Teladoc
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Teladoc
Der Hebel muss zwischen 2 und 20 liegen
| Name | Hebel | KO | Emittent |
|---|
| Name | Hebel | KO | Emittent |
|---|
Quelle: Zacks
Nachrichten zu Teladoc Inc
Analysen zu Teladoc Inc
| Datum | Rating | Analyst | |
|---|---|---|---|
| 02.11.2018 | Teladoc Buy | Chardan Capital Markets | |
| 03.08.2018 | Teladoc Buy | Chardan Capital Markets | |
| 05.06.2018 | Teladoc Buy | Canaccord Adams | |
| 15.03.2018 | Teladoc Hold | Deutsche Bank AG | |
| 28.02.2018 | Teladoc Buy | Chardan Capital Markets |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 02.11.2018 | Teladoc Buy | Chardan Capital Markets | |
| 03.08.2018 | Teladoc Buy | Chardan Capital Markets | |
| 05.06.2018 | Teladoc Buy | Canaccord Adams | |
| 28.02.2018 | Teladoc Buy | Chardan Capital Markets | |
| 08.12.2017 | Teladoc Buy | Deutsche Bank AG |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 15.03.2018 | Teladoc Hold | Deutsche Bank AG | |
| 18.09.2017 | Teladoc Neutral | Robert W. Baird & Co. Incorporated |
| Datum | Rating | Analyst | |
|---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv | |||
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Teladoc Inc nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen